Close Menu

codevelopment agreement

The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.

The companies will develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.

The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

Both companies are working together to market both companies' technology for long-read DNA sequencing. 

Toma Biosciences will use Seraseq biosynthetic reference material technology to develop and validate its Toma OS-Seq reagent kits. 

The diagnostic test is intended to help physicians decide if and how to use Mirati's targeted therapy in non-small cell lung cancer patients. 

The agreement calls for HTG to develop several in vitro diagnostics on Thermo Fisher's next-generation sequencing-based Ion PGM Dx system.

The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.

They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.

The companies will each create products using Agilent's SureSelect target enrichment technology on 10x's Chromium platform.


A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.